A New Strategy, Not an Ingredient Approval
On 8 September 2026, the European Commission adopted a new strategic approach to agri-food research and innovation. Its announcement, published the same day, links AgRI 2040, covering agriculture, forestry and rural areas, with Food 2040, covering food systems including fisheries and aquaculture. It emphasises testing and practical uptake alongside research, with end users and businesses involved in developing solutions. Commission announcement
The accompanying official factsheet was also released on 8 September. These are current policy publications, not evidence that a particular new ingredient is available, approved or ready for recurring deliveries. EU Publications Office factsheet record
For a purchasing team, the distinction is useful: an innovation can deserve attention without yet deserving a place in the production schedule. The commercial task is to define what must be demonstrated between an encouraging trial and a dependable purchase order.
What Buyers Should Take from the Announcement
Sourced context: The Commission identifies circularity and food and feed safety among shared priorities. Its approach seeks closer alignment between research and users' needs, while providing long-term direction without prejudging the next EU budget negotiations. Strategy announcement
Commercial interpretation: Treat this as a reason to improve the way new materials and processing approaches are evaluated, not as a purchasing instruction. The following questions are proposed buyer controls. They are not requirements introduced by the strategy, and they do not imply that any existing GT Nutritions product participates in an EU-funded project.
Define the Problem Before Assessing the Solution
Start with a specific purchasing or production constraint. Is the objective a more consistent specification, a different raw-material route, easier handling, or improved use of an existing side stream? Ask the proposer to identify which constraint its solution addresses and which remain unchanged.
Write a short acceptance brief before requesting samples. It should name the intended animal category and application, the existing reference material, the evidence needed and the decision owner. Leave performance targets to the responsible nutrition and technical teams rather than inserting a generic claim from a presentation.
This makes the evaluation testable. A trial that answers one defined question is easier to interpret than a trial expected to prove every possible commercial and sustainability benefit at once.
Separate a Good Sample from a Repeatable Specification
Request evidence from more than one production lot where available. Ask which results come from laboratory, pilot or commercial-scale production, and keep those categories visible in the evaluation file. Do not describe a pilot-scale result as an established production range.
Agree the sampling approach, analytical methods and reporting basis before comparing certificates. Record the origin and processing description alongside the results, and ask what happens when incoming raw materials differ from those used in the trial.
For a proposed side-stream ingredient, also request a clear explanation of how the material is identified, separated and traced. A circular-economy narrative should lead to more precise questions about the material, not replace them.
Keep Regulatory Classification Separate from Innovation Status
Sourced background: The Commission states that feed additives require authorisation before being placed on the market and provides a register linking to the relevant authorisation regulations. This is an existing regulatory framework, not a new permission created by the September strategy. Commission feed-additives guidance
Commercial interpretation: Ask your compliance specialist to determine the correct classification and applicable route for the actual product, intended use and destination. Do not apply the feed-additive procedure indiscriminately to every feed material, or assume that research participation settles classification.
Keep three decisions separate in the purchasing record: whether evaluation should continue, whether the intended use is eligible, and whether commercial release is authorised internally. A positive answer to the first does not settle the other two.
Test the Supply Arrangement, Not Just the Product
Before moving beyond a trial order, request a realistic production schedule, minimum order, packaging proposal, loading arrangement and specification-change procedure. Ask which parts are demonstrated today and which depend on future investment or commissioning.
Evaluate the offer using explicit assumptions for transport, storage, testing and any trial-related handling. Keep unconfirmed estimates separate from quoted costs. Where advance funding is proposed, distinguish paying for a defined shipment from financing development, and obtain the appropriate commercial and legal review.
A useful trial agreement should explain acceptance, rejection, traceability and who decides the next step. Preserve the option to stop after evaluation without implying an automatic commitment to recurring volumes.
The Next Date to Watch
The EU AgRI 2040 Conference is scheduled for 24-25 September 2026 in Brussels, with stakeholders contributing to future research and innovation priorities. As of this draft, that event is still ahead; no conference outcome is assumed here. Official conference page
For buyers, a useful follow-up is to review published outputs for problems relevant to their own supply chain. Record the specific evidence or collaboration sought, rather than treating every announced initiative as a near-term sourcing alternative.